Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells 412 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 412 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $40.00, for a total transaction of $16,480.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Harold Bernstein also recently made the following trade(s):

• On Friday, January 2nd, Harold Bernstein sold 4,432 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.43, for a total transaction of $179,185.76.
• On Monday, December 29th, Harold Bernstein sold 45,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.56, for a total transaction of $1,825,200.00.

Maze Therapeutics Price Performance

Shares of MAZE stock traded down $0.26 on Tuesday, hitting $38.37. 241,160 shares of the stock traded hands, compared to its average volume of 330,787. Maze Therapeutics, Inc. has a 52 week low of $6.71 and a 52 week high of $43.29. The firm has a 50 day simple moving average of $37.15 and a two-hundred day simple moving average of $25.26. The firm has a market cap of $1.85 billion and a price-to-earnings ratio of -1.84.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Wall Street Analyst Weigh In

Several research analysts have weighed in on MAZE shares. HC Wainwright upped their price target on Maze Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, December 3rd. Wells Fargo & Company began coverage on shares of Maze Therapeutics in a research report on Thursday, December 4th. They set an “overweight” rating and a $55.00 target price for the company. Guggenheim reaffirmed a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Friday, December 19th. Wedbush lifted their price target on shares of Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Finally, Lifesci Capital raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Three research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $43.38.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of MAZE. Invesco Ltd. purchased a new position in Maze Therapeutics in the first quarter worth about $226,000. Goldman Sachs Group Inc. purchased a new stake in Maze Therapeutics during the first quarter valued at approximately $145,000. Ensign Peak Advisors Inc bought a new stake in shares of Maze Therapeutics in the 2nd quarter valued at approximately $227,000. Frazier Life Sciences Management L.P. boosted its holdings in shares of Maze Therapeutics by 10.6% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock worth $56,040,000 after purchasing an additional 438,274 shares during the period. Finally, Nuveen LLC purchased a new position in shares of Maze Therapeutics in the 1st quarter worth approximately $125,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.